Health Outcomes
0
Stanford Medicine Innovation Professor
alyce_profile_2022.jpg PhD, MPP

Alyce Adams is a Professor of Health Policy and of Epidemiology and Population Health in the Stanford School of Medicine; Associate Chair, Partnership and Community Engagement for the Department of Health Policy; and Associate Director for Health Equity and Community Engagement in the Stanford Cancer Institute. Focusing on racial and socioeconomic disparities in chronic disease treatment outcomes, Dr. Adams' interdisciplinary research seeks to evaluate the impact of changes in drug coverage policy on access to essential medications, understand the drivers of disparities in treatment adherence among insured populations, and test strategies for maximizing the benefits of treatment outcomes while minimizing harms through informed decision-making. Prior to joining Stanford School of Medicine, Dr. Adams was Associate Director for Health Care Delivery and Policy and a Research Scientist at the Kaiser Permanente Division of Research, as well as a Professor at the Bernard J. Tyson Kaiser Permanente School of Medicine. From 2000 to 2008, she was an Assistant Professor in the Department of Population Medicine (formerly Ambulatory Care and Prevention) at Harvard Medical School and Harvard Pilgrim Health care. She received her PhD in Health Policy and an MPP in Social Policy from Harvard University. She is Vice Chair of the Board of Directors for AcademyHealth and a former recipient of the John M. Eisenberg Excellence in Mentoring Award from Agency for Healthcare Research and Quality and an invited lecturer on racial disparities in health care in the 2014/2015 National Institute of Mental Health Director’s Innovation Speaker Series.

Professor, Epidemiology and Population Health
Professor, Health Policy
Professor, Pediatrics (by courtesy)
CV
Date Label
Paragraphs

With vaccines against SARS-CoV-2, the virus that causes Covid-19, on the near-term horizon, U.S. policymakers are focusing on how to ensure that Americans get vaccinated. This challenge has been compounded by reports that White House officials are exerting undue influence over the agencies that would ordinarily lead such efforts, the Food and Drug Administration and the Centers for Disease Control and Prevention.

All Publications button
1
Publication Type
Commentary
Publication Date
Journal Publisher
STAT News
Authors
Michelle Mello
Number
2020
Paragraphs

Stanford Health Policy’s Joshua Salomon, a professor of medicine and senior fellow at the Freeman Spogli Institute for International Studies, and colleagues developed a mathematical model to examine the potential for contact tracing to reduce the spread of the coronavirus. They modeled contact tracing programs in the context of relaxed physical distancing under different assumptions for case detection, tracing coverage and the extent to which contact tracing can lead to effective quarantine and isolation.

All Publications button
1
Publication Type
Journal Articles
Publication Date
Journal Publisher
JAMA Network Open
Authors
Joshua Salomon
Number
2020
Paragraphs

In a recent perspective published by the New England Journal of Medicine(NEJM), Stanford Law student Alexandra Daniels analyzed a growing body of federal litigation brought by prisoners with the hepatitis C virus (HCV) who are seeking access to treatment for their condition. With co-author and mentor, Law Professor David Studdert — also a professor of medicine at Stanford Health Policy — Daniels documented the dire public health problem of HCV in prisons.

All Publications button
1
Publication Type
Journal Articles
Publication Date
Journal Publisher
New England Journal of Medicine
Authors
David Studdert
Number
2020

Encina Commons Room 222,
615 Crothers Way,
Stanford, CA 94305-6006

(650) 724-3545
0
Research Scholar, Health Policy
yifan.jpg PhD

Yifan Zhang is a Social Science Research Scholar at Stanford University School of Medicine. She is interested in applying statistical analysis methods in health policy research in scenarios where health risk heterogeneity exists. At Stanford Health Policy, she has participated in projects examining drivers’ accident risks, physicians’ malpractice, gun violence, and secondary insurance markets. Dr. Zhang has engaged from the beginning of a five-year collaboration among researchers in multiple institutions and government agencies to construct an extensive database of firearm purchasers that permits the analysis of risk factors of firearm injuries.

Before joining Stanford, Dr. Zhang was a Research Associate at Center for Biostatistics in AIDS Research at Harvard T.H. Chan School of Public Health. She received a BSc in Actuarial Science from The University of Hong Kong, an MSc and a PhD from Harvard University.

CV
Paragraphs

Taiwan is 81 miles off the coast of mainland China and was expected to have the second highest number of cases of coronavirus disease 2019 (COVID-19) due to its proximity to and number of flights between China. The country has 23 million citizens of which 850 000 reside in and 404 000 work in China. In 2019, 2.71 million visitors from the mainland traveled to Taiwan. As such, Taiwan has been on constant alert and ready to act on epidemics arising from China ever since the severe acute respiratory syndrome (SARS) epidemic in 2003. Given the continual spread of COVID-19 around the world, understanding the action items that were implemented quickly in Taiwan and assessing the effectiveness of these actions in preventing a large-scale epidemic may be instructive for other countries.

All Publications button
1
Publication Type
Journal Articles
Publication Date
Journal Publisher
JAMA Network
Authors
C. Jason Wang
Number
2020
Authors
Noa Ronkin
News Type
News
Date
Paragraphs

Rapid population aging is transforming societies around the world, and the Asia-Pacific region is on the frontlines of this unprecedented demographic shift. Life expectancy in Japan, South Korea, and much of urban China has now outpaced that of the United States and other high-income countries. With this triumph of longevity, however, comes a host of health, social, and economic challenges.

Longer lifespans will necessitate working to older ages, “but extending work lives will only be feasible if the added years are healthy ones, and will only be equitable if the least advantaged also benefit from healthy aging,” writes APARC Deputy Director and Asia Health Policy Program Director Karen Eggleston in her new book, Healthy Aging in Asia. “The great blessing of longer lives dims when clouded by pain, disability, and loss of dignity.”

[Listen to our conversation with Eggelston about the book and continue reading below. To receive stories like this directly in your inbox sign up for APARC newsletters]

Shorenstein APARC · Healthy Aging In Asia | Karen Eggleston

Image
Poster featuring the book Healthy Aging in Asia


Societies around the world must reduce disparities in health outcomes and address the older age-associated rise in the burden of noncommunicable diseases (NCDs) such as diabetes, hypertension, and cancer. Indeed, the COVID-19 pandemic has underscored the vulnerability of older adults suffering from NCDs to newly emerging pathogens and the importance of building long-term, resilient health systems.


How are health systems in Asia promoting evidence-based policies for healthy aging? What strategies have they used to prevent NCDs, screen for early disease detection, raise the quality of care, improve medication adherence, reduce unnecessary hospitalizations, and increase “value for money” in health spending?

The concise chapters in Healthy Aging in Asia examine these questions, covering multiple aspects of policy initiatives and economic research on healthy longevity in diverse Asian economies — from cities such as Singapore and Hong Kong to powerhouses such as Japan, India, and China — as they transform their health systems to support wellbeing in older age. Eggleston edited and contributed multiple chapters to this new volume, now available via Brookings Institution Press. This publication is part of APARC’s in-house series with the Brookings Institution.

Dr. Karen Eggleston

Karen Eggleston

Senior Fellow at the Freeman Spogli Institute for International Studies, Director of the Asia Health Policy Program, and Deputy Director of the Shorenstein Asia-Pacific Research Center
Full Biography

Read More

Karen Eggleston speaking to an online panel.
News

Karen Eggleston Testifies on China’s Healthcare System to Congressional Review Commission

Asia health policy expert Karen Eggleston provides testimony for a U.S.-China Economic and Security Review Commission hearing on China's domestic healthcare infrastructure and the use of technology in its healthcare system amid COVID-19.
Karen Eggleston Testifies on China’s Healthcare System to Congressional Review Commission
Elderly Chinese citizens sit together on a park bench.
Q&As

Karen Eggleston Examines China’s Looming Demographic Crisis, in Fateful Decisions

Karen Eggleston Examines China’s Looming Demographic Crisis, in Fateful Decisions
Michael McFaul, Xueguang Zhou, Karen Eggleston, Gi-Wook Shin, Don Emmerson, and Yong Suk Lee
News

FSI Hosts APARC Panel on COVID-19 Impacts in Asia

Scholars from each of APARC's programs offer insights on policy responses to COVID-19 throughout Asia.
FSI Hosts APARC Panel on COVID-19 Impacts in Asia
All News button
1
Subtitle

Asia health policy expert Karen Eggleston’s new volume, ‘Healthy Aging in Asia,’ examines how diverse Asian economies – from Singapore and Hong Kong to Japan, India, and China – are preparing for older population age structures and transforming health systems to support patients who will live with chronic disease for decades.

Subscribe to Health Outcomes